BrainsWay invests $1.5M in Chicago mental health clinic operator Hopemark Health
What's the deal? BrainsWayDealroom has a profile for this one. Try Dealroom → , a publicly traded neurostimulation company, is taking a minority stake in Hopemark HealthDealroom has a profile for this one. Try Dealroom →, which operates multiple mental health clinics in the greater Chicago area. The initial investment is $1.5M, with potential for an additional $1.5M tied to milestones. BrainsWay's stake takes the form of a preferred, annually compounding security with a redemption mechanism.
Hopemark Health is the collective name for APS Innovations LLC and its subsidiary Advanced Psychiatric Management LLC, a management services organisation servicing several clinics in Illinois.
Why now? This deal is the latest in a series of minority-stake investments BrainsWay has made in North American mental health providers. The company, which makes Deep Transcranial Magnetic Stimulation (Deep TMS) devices, is pursuing a deliberate strategy of backing growth-oriented clinical platforms to expand access to its technology.
"Our minority stake approach allows BrainsWay to continue to be laser-focused on the continuous advancement of its business and technology," said Hadar Levy, BrainsWay's chief executive officer.
Hopemark's chief executive officer, Dr. Abid Nazeer, said BrainsWay brings "not only growth capital, but a deep understanding of interventional psychiatry and operational best practices that will help us scale efficiently."
What could go wrong? Minority-stake investments in clinical operators carry inherent risks. BrainsWay has limited control over Hopemark's operations, and the success of the deal hinges on whether the clinics can grow patient volumes — particularly for interventional psychiatry treatments like Deep TMS. If adoption stalls or reimbursement landscapes shift, the investment thesis weakens.
The signal: BrainsWay, classified as a late-growth-stage company on Dealroom, is systematically building a portfolio of minority stakes in early-growth clinical platforms like Hopemark Health — a playbook that blurs the line between medical device vendor and healthcare investor. The approach suggests that in interventional psychiatry, where patient awareness and clinic capacity remain bottlenecks, controlling distribution through capital may prove as strategic as advancing the underlying technology itself.
Read more: globenewswire.com
